Empagliflozin granted fast track designation by FDA for reducing the risk of kidney disease progression

The drug, which is being investigated to reduce the risk of kidney disease progression and cardiovascular death in adults with chronic kidney disease, was determined to address the “urgent need” for new treatment options for people living with the disease.

PharmaTimes